DECREASED BREADTH OF THE ANTIBODY RESPONSE TO THE SPIKE PROTEIN OF SARS-CoV-2 AFTER REPEATED VACCINATION

Lydia Horndler¹, Pilar Delgado¹, Salvador Romero-Pinedo², Marina Quesada², Ivaylo
Balabanov¹, Rocío Laguna-Goya³, Patricia Almendro-Vázquez³, Miguel A. Llamas⁴,
Manuel Fresno¹, Estela Paz-Artal^{3,5}, Hisse M. van Santen¹, Stela Álvarez², Asunción
Olmo² and Balbino Alarcón¹

¹Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones
Científicas (CSIC), Universidad Autónoma de Madrid, 1 Nicolás Cabrera, 28049
Madrid, Spain

²VITRO SA, Avenida del Conocimiento 100, PT de la Salud, 18016 Granada, Spain

³Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid,
Spain

⁴EMPIREO Diagnóstico Molecular SL, 127 Fuencarral Street, 28004 Madrid, Spain

⁵Department of Immunology, Ophthalmology and ENT, Universidad Complutense de
Madrid, Madrid, SpainCorrespondence should be addressed to B.A.
(balarcon@cbm.csic.es)

Centro de Biología Molecular, Nicolás Cabrera 1, Universidad Autónoma de Madrid,
Cantoblanco, Madrid 28049, Spain. Phone: 34-911964555; FAX: 34-911964420

Running Title: Decreased breadth after boost

25 **ABSTRACT**

26 The rapid development of vaccines to prevent infection by SARS-CoV-2 virus causing
 27 COVID-19 makes necessary to compare the capacity of the different vaccines in terms
 28 of development of a protective humoral response. Here, we have used a highly
 29 sensitive and reliable flow cytometry method to measure the titers of antibodies of the
 30 IgG1 isotype in blood of healthy volunteers after receiving one or two doses of the
 31 vaccines being administered in Spain. We took advantage of the multiplexed capacity
 32 of the method to measure simultaneously the reactivity of antibodies with the S protein
 33 of the original strain Wuhan and the variants B.1.1.7 (Alpha), B.1.617.2 (Delta) and
 34 B.1.617.1 (Kappa). We found significant differences in the titer of anti-S antibodies
 35 produced after a first dose of the vaccines ChAdOx1 nCov-19/AstraZeneca, mRNA-
 36 1273/Moderna, BNT162b2/Pfizer-BioNTech and Ad26.COV.S/Janssen. Most
 37 important, we found a relative reduction in the reactivity of the sera with the Alpha,
 38 Delta and Kappa variants, versus the Wuhan one, after the second boosting
 39 immunization. These data allow to make a comparison of different vaccines in terms of
 40 anti-S antibody generation and cast doubts about the convenience of repeatedly
 41 immunizing with the same S protein sequence.

42

43 **Keywords:** SARS-CoV-2 / S protein / flow cytometry method / vaccines / antibody
 44 breadth

45 INTRODUCTION

46 Vaccines to prevent the worst effects of infections by SARS-CoV-2 virus causing
 47 COVID-19 have been rapidly developed. This unprecedented fast development of
 48 vaccines has allowed a significant reduction in the number of deaths caused by
 49 COVID-19 as well as in the number of patients admitted to the intensive care units of
 50 hospitals. In Spain, the immunity reached by the widespread vaccination, and immunity
 51 due to previous infections, is likely responsible for the low number of deaths caused by
 52 the so-called the fifth-wave by the end of July 2021, in spite reaching a number of
 53 reported infections similar to that of previous waves in the fall of 2020 and beginning of
 54 year 2021 that caused a much higher number of deaths
 55 (<https://covid19.who.int/region/euro/country/es>). The vaccines that have been more
 56 commonly administered in Spain are the mRNA vaccines BNT162b2 (BNT) generated
 57 by BioNTech/Pfizer, mRNA-1273 by Moderna, and the adenovirus-based vaccines
 58 ChaAdOx1 nCov-19 (ChAd) and Ad26.COV2.S (Ad26) by Oxford
 59 University/AstraZeneca and Janssen/Johnson&Johnson, respectively. All vaccines
 60 were demonstrated to be safe and protective in clinical trials [(2–5)], although reports of
 61 rare cases of thrombotic thrombocytopenia associated to both the ChAd and Ad26
 62 vaccines have been published [5,6]. However, the emergence of variants of concern
 63 (VOC) of SARS-CoV-2, specifically the Delta variant (B.1.617.2) with a very high
 64 transmission capacity(6) is threatening the vaccination strategies in Europe and the
 65 USA, given the fact that the efficacy of vaccines against the Delta variant is reduce [8],
 66 and fully vaccinated people can become infected and spread the virus efficiently to
 67 others [9]. The possibility of giving a third boosting vaccination to immunosuppressed
 68 patients to increase the titers of antibodies to the spike (S) protein is being considered
 69 [10]. Moreover, the spread of the Delta variant even in fully vaccinated people is
 70 making authorities of different countries consider the possibility of administering a third
 71 dose to the general population (<https://english.elpais.com/society/2021-07->

72 [23/everything-pointing-to-need-for-a-third-covid-19-vaccine-dose-says-spanish-health-](#)
73 [minister.html](#)). The capacity of the Delta variant to infect vaccinated individuals seems
74 to correlate with its ability to escape neutralization by antibodies produced in response
75 to vaccines(6).

76 Serological tests are usually established by detecting the presence of viral
77 antigen-specific IgG or IgM in the serum of individuals using recombinant fragments of
78 the S or N proteins and tests based on ELISA or lateral flow assay [11,12]. A
79 disadvantage of those tests is that neutralizing antibodies are not directed against the
80 N protein and that recombinant fragments of the S protein miss the quaternary
81 structure of the protein trimer, which is the native form of the spike protein in the viral
82 envelope. Therefore, part of the neutralizing antibodies directed against the native S
83 trimer could be missed in serological tests based on the expression of recombinant
84 proteins. Recently, we have described a flow cytometry (FC) test that makes use of the
85 cell line of hematopoietic origin Jurkat to express the native S protein of SARS-CoV-2
86 together with a truncated form of the human EGF receptor (huEGFRt) as a normalizing
87 tool [13]. The method allows the accurate determination of seropositivity and the
88 measurement of antibody titers in sera from post-convalescent patients [13]. Here, we
89 have used this FC method to compare the production of antibodies against the S
90 protein in response to the prime immunization and the booster immunization of the four
91 most common vaccines being used in Spain. In addition, we have used the multiplexed
92 capacity of the method to simultaneously measure the reactivity of sera from
93 vaccinated individuals with the S protein of the original Wuhan isolate versus the Alpha,
94 Delta and Kappa isolates as example of VOC. Our results help to stir the debate about
95 the convenience of a third dose of the same vaccines.

96

97 MATERIALS AND METHODS

98 Cells

99 The human T-cell line Jurkat clone E6-1 was acquired from ATCC (TIB-152) and was
100 maintained in complete RPMI 1640 supplemented with 5% fetal bovine serum (FBS,
101 Sigma) in a 5% CO₂ incubator. Human embryonic kidney HEK293T cells (ATCC CRL-
102 3216) were maintained in DMEM supplemented with 10% FBS in a 5% CO₂ incubator.
103 All cell lines were routinely tested for the absence of mycoplasma.

104 Lentiviral vector and Jurkat cell transduction

105 The generation of Jurkat-S cells expressing the spike protein of the Wuhan variant has
106 been previously described [(1)]. To express the full-length spike S protein of the Alpha
107 (B.1.1.7), Delta (B.1.617.2) and Kappa (B.1.617.1) SARS-CoV-2 variants in the Jurkat
108 cell line, we used the lentiviral vector based on the ephIV-7 plasmid and the spike S
109 proteins sequences were obtained from the Public Health England database
110 (<https://www.gov.uk/coronavirus>) and synthesized by the company Eurofins Genomics.
111 Wuhan and Alpha (B.1.1.7) variants were expressed in Jurkat CD3⁺ cells while Delta
112 (B.1.617.2) and Kappa (B.1.617.1) variants were expressed in Jurkat CD3⁻ cells. The
113 Jurkat CD3⁻ cells were generated in our lab using CRISPR/Cas9 system. The EGFP
114 sequence was obtained from the vector pEGFP-C1 (Addgene). Plasmid constructions
115 were generated by the Gibson Assembly® method.

116 For transduction, lentiviral-transducing supernatants were produced from
117 transfected packaging HEK-293T cells as described previously [20]. Briefly, lentiviruses
118 were obtained by co-transfecting plasmids pCMV-dR (gag/pol) and pMD2.G (VSV
119 envelope protein), using the JetPEI transfection reagent (Polyplus Transfection). Viral
120 supernatants were obtained after 24 and 48 hours of transfection. Polybrene (8 µg/mL)
121 was added to the viral supernatants prior to transduction of Jurkat cells. A total of 5x10⁵
122 Jurkat cells were plated in a P24 flat-bottom well in 350 µL of RPMI, and 350 µL of viral

123 supernatant were added. Cells were centrifuged for 90 minutes at 2200 rpm and 32°C
124 and left in culture for 24 hours. Transduced GFP+ or HuEGFRt+ cells were selected by
125 FACS sorting 48 h later and expanded in culture.

126 **Human sera**

127 A total of 700 human sera were tested. A first set of 50 sera from Empireo obtained in
128 the year 2020 after the first wave of the COVID-19 pandemics. Serum donors filled in a
129 questionnaire to allow their clinical classification according to the following parameters:
130 Asymptomatic, no symptoms; Mild, 3 or more of the following symptoms: non-
131 productive cough, hyperthermia, headache, odynophagia, dyspnea, asthenia, myalgia,
132 ageusia, anosmia, cutaneous involvement; Moderate, 3 or more of the above
133 symptoms plus gastrointestinal symptoms, or more than 3 of the above for 7 or more
134 days; Moderate-Severe, 3 or more of the above symptoms plus pneumonia; Severe,
135 pneumonia requiring hospitalization and intubation. A second set of 52 serum samples
136 were selected from the study “Immune response dynamics as predictor of COVID-19
137 disease evolution. Implications for therapeutic decision-making” from the Hospital
138 Universitario La Princesa (HUP) approved by the Research Ethics Committee (no.
139 #4070). A third set of 250 sera from nursery homes and VITRO employees. A fourth
140 set of 40 serum samples were obtained from teachers and employees of a secondary
141 school in Madrid (name not revealed to keep anonymity). Finally, a fifth cohort of 250
142 serum samples were obtained from capillary blood of volunteers working at the
143 CBMSO in the period of January-July 2021, included in the study “*ACE2 as a*
144 *biomarker with utility for identification of high risk population for SARS-CoV-2 infection*
145 *and prognosis of evolution in COVID-19*” approved by the Research Ethics Committee
146 (no. #2352). The ethical approvals for the use of the samples applied to the current
147 study. All participants provided written consent to participate in the study which was
148 performed according to the EU guidelines and following the ethical principles of the
149 Declaration of Helsinki.

150 **Flow cytometry**

151 For the study of relative binding of antibodies to the Alpha versus the Wuhan variants,
 152 a 1:1 mix of Jurkat-S(wuhan) and Jurkat-S(Alpha) cells were incubated for 30 min on
 153 ice with 1:50 dilutions of human sera in phosphate-buffered saline (PBS), 1% bovine
 154 serum albumin (BSA), 0.02% sodium azide. Cells were spun for 5 min at 900 g and the
 155 pellet was resuspended in PBS-BSA buffer and spun to eliminate the excess of
 156 antibody. Two additional washes were carried out. The cell pellet was finally
 157 resuspended in a 1:200 dilution of mouse anti-human IgG1 Fc-PE (Ref.: 9054-09,
 158 Southern Biotech) and a 1:200 dilution of the Brilliant Violet 421™ anti-human EGFR
 159 Antibody (Ref.: 352911, Biolegend) in PBS-BSA. Samples were then washed, labeled
 160 with the viability dye 7AAD and analyzed on a FACSCanto II flow cytometer (Becton-
 161 Dickinson) and the data were analyzed with FlowJo software (BD). For the study of the
 162 four variants simultaneously, 1:1:1:1 mix of Jurkat-S(wuhan), Jurkat-S(Alpha) Jurkat-
 163 S(Delta) and Jurkat-S(Kappa) cells were incubated as previously described, but
 164 adding in a dilution 1:200 of the APC anti-human CD3 antibody (BD Ref.: 317317) to
 165 discriminate between CD3+ and CD3⁻ cells.

166 **Confocal microscopy**

167 Spike protein expression in cell membrane was confirmed by confocal microscopy. A
 168 total of 10⁶ cells expressing either of the VOCs were incubated with anti -SARS-CoV-2
 169 (COVID-19) spike antibody (GeneTex Cat No. GTX632604) at a 1:150 dilution in
 170 phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA), and 0.02% sodium
 171 azide for 30 minutes at room temperature, followed by Alexa 555 Donkey anti-mouse
 172 IgG1 (ThermoFisher, Cat No A-31570). Cells were then blocked with a 1:100 dilution of
 173 normal mouse serum for 15 minutes. After that, cells were labeled with anti-CD45-PE
 174 (BD, Cat No. 555483) at a 1:200 dilution for 30 minutes at room temperature. Samples
 175 were allowed to bind to poly-L-lysine-coated glass for 30 min and fixed for 10 min at

176 room temperature with 4% paraformaldehyde. Cell nuclei were stained with 1 µg/ml
177 DAPI in PBS for 5 min, and finally, samples were mounted with Prolong Antifade
178 (Molecular probes). Samples were observed by LSM 710 laser scanning confocal
179 microscope. Image processing was performed using Zen software.

180 **Statistics**

181 One-way ANOVA tests for column analysis of different groups. All data was analyzed
182 using the GraphPad Prism 7 software. Serum samples were received coded from the
183 providers and the experimentalists were blinded to their nature until all data analysis
184 was finalized. Sample analysis was carried out in duplicate or triplicate and all
185 experiments were repeated a minimum of two times.

186 RESULTS

187 Comparison of IgG1 anti-S titers in response to the four (ChaAd, Moderna, 188 BNT and Ad26) vaccines

189 We previously used a lentiviral vector to express the full spike “S” protein of SARS-
190 CoV2 with the original Wuhan-1 sequence, followed by a truncated human EGFR
191 protein (huEGFRt) linked by a T2A self-cleaving sequence in transduced cells [13].
192 This system allows expression of the two proteins from a monocistronic mRNA. We
193 produced transducing supernatants to express the construct in the human leukemic cell
194 line Jurkat. The S protein was previously tested to be folded in its native form at the
195 plasma membrane of Jurkat cells since it was found to be trimeric by electrophoresis in
196 polyacrylamide gels under native conditions and to be able to promote the formation of
197 syncytia between Jurkat and ACE2+ cells [13]. Taking advantage of the fact that the
198 expression of S protein is coupled to that of huEGFRt, we calculated a ratio of mean
199 fluorescence intensities of antibodies against S versus an antibody against huEGFR as
200 direct estimation of the relative quantity of immunoglobulins against the S protein in
201 sera or other fluids from different donors. A conversion between S/EGFR MFI ratios
202 and international WHO standards in BAU/mL is shown in Fig S1. Using this system, we
203 interrogated what was the relative humoral response, in terms of IgG1 production, to
204 the different vaccines used in Spain from January to August 2021. Since the
205 Ad26.COV2.S (Ad26) vaccine was initially planned to be given in one dose and not in
206 two, prime-boost, as the other three vaccines (BNT162b2 [BNT], mRNA-1273
207 [Moderna], and ChaAdOx1 nCov-19 (ChAd)), we first compared the titer of antibodies
208 elicited in vaccinated healthy individuals 3-4 weeks after the first dose. We found that
209 ChAd (n=37) induced lower titers of IgG1 antiS antibody than Moderna (n=54) and BNT
210 (n=75) (Fig 1A). However, the titers elicited in response to ChAd and Ad26 (n=11) were
211 not significantly different. Compared to the titer of antibody present in a cohort of

212 patients recovered from SARS-CoV-2 infection between March and May 2020
 213 (<https://covid19.who.int/region/euro/country/es>) (Patients 2020, n=58, Fig 1A),
 214 vaccination with one dose of ChAd elicited significantly lower titers ($P<0.0001$, One-
 215 way ANOVA test). By contrast, one dose of either BNT or Moderna induced higher
 216 titers of antibody than those present in Patients 2020. Unfortunately, the number of
 217 samples in the Ad26 group was insufficient to establish a significant comparison with
 218 the Patients 2020 cohort. Altogether, these data suggest that the two RNA vaccines
 219 (BNT and Moderna) are more efficient than the two adenovirus-based vaccines (Ad26
 220 and ChAd) at inducing IgG1 anti-S antibodies.

221 We next compared the titers of anti-S IgG1 generated in response to a priming and a
 222 booster dose of the ChAd, Moderna and BNT vaccines. The second dose of ChAd
 223 vaccine (PD2; n=39) substantially increased the titer of antibodies to a level
 224 comparable to those of Patients 2020 and to those of individuals vaccinated with two
 225 doses of Moderna (PD2; n=52; Fig 1B). Nonetheless, the antibody titers elicited by two
 226 doses of BNT (PD2, n=119) were still significantly higher than those generated in
 227 response to two doses of ChAd (Fig 1B). Interestingly, the titers of IgG1 generated in
 228 response to two doses (PD2) of either Moderna or BNT, were not significantly higher
 229 than those generated in response to the first priming dose (PD1, Fig 1B). Nonetheless,
 230 this result does not argue against other effects of the booster dose of Moderna and
 231 BNT vaccines on the humoral response, like improving the memory response or the
 232 duration of the protective effect.

233 **IgG1 titers against the S protein of the Alpha (B.1.1.7) VOC produced after** 234 **priming-booster vaccination**

235 The flow cytometry Jurkat-S method can be easily multiplexed to measure
 236 simultaneously the generation of different antibodies to a single protein or to several
 237 proteins [13]. We decided to use this property to measure the generation of antibodies

238 against the S protein of the Wuhan strain in comparison with the antibodies able to bind
239 to the S protein of the Alpha (B.1.1.7) VOC. We thought this comparison might be
240 relevant given that the present vaccines were all generated against the Wuhan strain
241 sequence. The S protein sequence of the Alpha VOC differs in just 7 positions from
242 that of the Wuhan strain (Fig S2). The Alpha VOC became dominant in Spain during
243 the spring of 2021 ([https://theconversation.com/the-uk-variant-is-likely-deadlier-more-](https://theconversation.com/the-uk-variant-is-likely-deadlier-more-infectious-and-becoming-dominant-but-the-vaccines-still-work-well-against-it-156951)
244 [infectious-and-becoming-dominant-but-the-vaccines-still-work-well-against-it-](https://theconversation.com/the-uk-variant-is-likely-deadlier-more-infectious-and-becoming-dominant-but-the-vaccines-still-work-well-against-it-156951)
245 [156951](https://theconversation.com/the-uk-variant-is-likely-deadlier-more-infectious-and-becoming-dominant-but-the-vaccines-still-work-well-against-it-156951)).and therefore, we included in this and previous experiments a cohort of sera
246 from patients recovered from infection by SARS-CoV-2 between March and May 2021
247 (Patients 2021, n=20, Figs 1 and 2).

248 In order to detect the presence of antibodies against the S protein of the Alpha VOC,
249 we cloned the S sequence of the variant (Fig S2) into the same lentiviral vector used to
250 generate the original Jurkat-S cells [13] but replaced the huEGFRt reporter by EGFP,
251 and generated Jurkat cells stably expressing the S protein of the Alpha variant and
252 EGFP. Using this new Jurkat-S cells (from now on termed Jurkat-S[Alpha]) we could
253 measure the titers of IgG1 antibody generated against the S protein of the Alpha VOC.
254 Our positive control serum from a patient recovered of infection during the first wave of
255 COVID-19 in March 2020 was titrated in both Jurkat-S[Wuhan] and Jurkat-S[Alpha]
256 generating very similar results (Fig S3). We used a non-saturating 1:50 dilution of all
257 sera, as in Fig 1, to compare the response to prime-boost vaccination in terms of
258 generation of IgG1 antibodies capable of binding the Wuhan and Alpha variants
259 simultaneously. We found similar results to those for the Wuhan strain (compare Fig 2A
260 with Fig 1B), namely that the second dose of ChAd significantly increased the titer of
261 antibodies compared to the first dose and that the second dose of Moderna and BNT
262 did not result in a significant increase of IgG1 anti-S titers compared to the first, priming
263 dose (P=0.43 and P=0.92, respectively; One-way ANOVA test).

264 Taking advantage of the distinct markers used for Jurkat-S(Wuhan) and Jurkat-
 265 S(Alpha) cells (EGFR and EGFP, respectively), we could mix equal numbers of both
 266 cell lines and incubate the cell mixture with dilutions of sera of patients recovered from
 267 infection with SARS-CoV-2 or vaccinated. The analysis by flow cytometry allowed to
 268 gate on the GFP+ cells to calculate the ratio of [fluorescence anti-S/GFP fluorescence]
 269 as a measurement of the titer of antibodies of the IgG1 isotype against the S protein of
 270 the Alpha variant (Fig 2B). Simultaneously, we could gate on the EGFR+ cells to
 271 calculate the ratio of [fluorescence anti-S/fluorescence anti-EGFR] as a measurement
 272 of the titer of antibodies of the IgG1 isotype against the S protein of the Wuhan strain.
 273 The combination of Jurkat-S(Wuhan) and Jurkat-S(Alpha) cells in the same experiment
 274 allows to calculate a ratio of ratios (S/GFP vs S/EGFR) that serves to compare sera
 275 from vaccinated volunteers in terms of their relative reactivity with the S protein of the
 276 Wuhan and Alpha VOC. The mixing of both cell types in this setting would allow the S
 277 protein of Alpha to compete with the S protein of Wuhan in order to trap the highest
 278 affinity IgG1 antibodies. So, this assay would theoretically serve to detect relative
 279 binding to one or other variant by antibodies that have experimented affinity maturation,
 280 typical of secondary humoral responses. Interestingly, the second dose of Moderna
 281 and the second dose of BNT caused a relative decrease in the reactivity of the
 282 antibodies with the Alpha VOC in comparison with the Wuhan-1 isolate (Fig 2C). The
 283 second dose of ChAd did not cause either an increase or a decrease in the relative
 284 recognition of the S protein of Alpha compared to Wuhan.

285 A comparison of the relative reactivity of sera from vaccinees with those of
 286 people recovered from infection in 2020 and 2021, showed that antibodies produced in
 287 response to the second dose of either of the three vaccines were relatively less
 288 reactive with the Alpha strain than those produced by natural infection not only in 2021
 289 but also in 2020 (Fig 2C). Those results suggest that the booster immunization with the

290 second dose of the three vaccines, based on the sequence of the Wuhan strain, might
291 impoverish the reactivity of the antibodies with emergent VOC of SARS-CoV-2.

292 **General decrease of relative reactivity against VOCs after booster** 293 **vaccination**

294 To determine if the detected decrease in anti –S (Alpha) relative reactivity after the
295 second dose of vaccines was also holding true for more recent VOCs of SARS-CoV-2,
296 we modified the Jurkat-S system to measure IgG1 binding to four variants: Wuhan,
297 Alpha, Delta (B.1.617.2) and Kappa (B.1.617.1). In order to be able to distinguish
298 Jurkat expressing the S protein of the Delta and Kappa variants from the Wuhan and
299 Alpha ones, using the same lentiviral vectors with the EGFR and EGFP markers, we
300 transduced a Jurkat CD3negative cell line generated in our lab by CRISPR/Cas9
301 deletion of the CD3 ζ subunit of the TCR. Those CD3 $^{-}$ Jurkat cells were transduced with
302 the lentiviral vectors co-expressing the S protein from Delta VOC and EGFR or co-
303 expressing the S protein from Kappa VOC and EGFP. Using this strategy, we could
304 mix the four Jurkat-S cell lines to incubated them simultaneously with serum samples
305 and later to measure IgG1 binding to the 4 VOCs using CD3, EGFR and GFP markers
306 (Figure 3). Fig 3, illustrates how the positive control serum and a negative control
307 serum stain the four VOC. A positive serum containing IgG1 binding to any of the 4
308 VOCs produces a diagonal, whereas a negative serum produces a flat line (Fig 3). The
309 S/EGFR and S/GFP MFI ratios produced by the positive control serum for those two
310 Jurkat-S(Delta) and Jurkat-S(Kappa) variants were reduced in terms of absolute
311 numbers, compared to the numbers generated with the MFI ratios for the Wuhan and
312 Alpha VOCs. The differences in the MFI ratio numbers could be intrinsic to the use of
313 CD3 $^{-}$ versus wild type Jurkat cells However, the titration of the positive control serum
314 produced a very similar result for the 4 variants (Fig S3), suggesting that the method is
315 valid to detect antibodies against the 4 variants. As control for correct expression of the
316 4 variants we carried out confocal microscopy analysis of the distribution of the S

317 protein. This showed that the S protein of the 4 variants was expressed at the plasma
318 membrane (Fig S4).

319 The effect of vaccination on the relative recognition of the S protein of the
320 Alpha, Delta and Kappa VOC versus that of the Wuhan strain was followed in sera
321 from volunteers of nursing homes who had recovered after infection in 2020 and 2021
322 and were later vaccinated with BNT (Table 1). Serum samples were taken just before
323 vaccination (pre-Vacc, n=46, Figure 4), 15-21 days after the first dose (PD1, n=49) and
324 4 weeks after the second dose (PD2, n=70) of the BNT vaccine.

325 The first dose of BNT resulted in a significant increase in antibody reactivity against the
326 Alpha and Kappa VOCs but not against the Wuhan and Delta ones (Fig 4A). Compared
327 to the pre-vaccination samples, the second dose of BNT (PD2) resulted in significantly
328 increased antibody titers against the four VOCs, although the differences between
329 antibody titers induced after PD1 and PD2 were not obvious for the Delta and Kappa
330 ones (Fig 4A). Indeed, the relative reactivity of IgG1 antibodies with the Alpha, Delta
331 and Kappa VOCs compared with that of the Wuhan strain, was significantly reduced
332 after the second dose of BNT compared to the first one (PD1 vs PD2, Fig 4B). These
333 results with samples from vaccinated donors of nursery homes support the Fig 2C data
334 suggesting that the booster vaccination results in a relative loss of recognition of the
335 Alpha, Delta, and Kappa VOC.

336 **DISCUSSION**

337 In this study we have measured the production of antibodies of the IgG1 isotype to the
338 spike protein of SARS-CoV-2 in response to the four different vaccines most frequently
339 used in Spain. We have compared those data with antibodies present in sera from
340 patients recovered from infection during the first wave of the COVID-19 pandemic in
341 March-June 2020 and with sera from patients recovered from infection during the fourth
342 wave between March-May 2021. Our results show that a priming first dose of the

mRNA vaccines BNT/Pfizer and Moderna significantly induced a higher antibody response against the S protein of the Wuhan strain than the two adenovirus-based vaccines ChAd and Ad26, and superior to the titers found in the cohorts of 2020 and 2021 patients. The booster immunization with a second dose did not increase the average titer of antibodies except for the ChAd vaccine. The booster immunization with ChAd resulted in antibody titers that were similar to those generated in response to the booster immunization with Moderna or to the patient cohorts of 2020 and 2021, but still lower than the titers generated in response to the booster immunization with BNT. Therefore, in summary, our results indicate that two doses of the ChAd, BNT and Moderna vaccines are able to induce antibody titers against the original Wuhan strain equal or even superior to those found in post-convalescent patients. However, the message is different when we compared the relative reactivity of the antibodies against the Alpha, Delta and Kappa variants versus the Wuhan strain. Although antibodies made in response to vaccines based on the original Wuhan strain sequence do also bind the other three variants, suggesting that most epitopes are conserved between the vaccine and the variant sequences, there is a relative loss of reactivity with the three VOCs compared to the Wuhan strain occurring upon administration of the booster dose of vaccine. This is somehow expected since repeated immunization with the same antigen sequence leads to the generation of higher affinity antibodies that fit better the epitopes of the immunogen. This increase in affinity has the negative side effect of reducing the “breadth” of the antibodies, that is, their capacity to bind to epitopes that differ slightly from those of the immunogen. Such effect of generating high-affinity antibodies that are however strain-specific has been widely documented in the search of broadly neutralizing antibodies for the human immunodeficiency virus (HIV) [14]. The long-term struggle, and still unsuccessful, to generate a vaccine that prevents infection by the tremendous diversity of clades and mutants of HIV, with the general conclusion that the tested vaccines are effective to prevent infection by the strain used for immunization but not by the myriad of variants found in the field [(8)]. Another example

371 is the result of vaccination with inactivated influenza virus isolated in immunization
372 campaigns, that result in an efficient neutralization of that particular seasonal variant of
373 influenza but results in reduced capacity to neutralize other variants [(9)]. By contrast,
374 antibody responses to natural infection are broad and exhibit different
375 immunodominance patterns(9). Another example of the different breadth in the
376 antibody responses elicited by natural infection versus vaccination is In regard to
377 COVID-19, a broad and sustained polyantigenic immunoreactivity against the S protein
378 and other viral proteins has also been found in COVID-19 patients, in this case
379 associated to the severity of symptoms(10). Our follow-up of the cohort of residents in
380 nursing homes that were vaccinated with two doses of BNT shows that the two doses
381 of vaccine increased the titers of anti-S antibodies against all the four variants.
382 However, compared with the effect of the first dose, the second dose of vaccine did not
383 result in further increases in the antibody titer against the Delta and Kappa variants and
384 had the negative counterpart of reducing the relative reactivity of the antibodies with all
385 three VOCs. This is relevant since the Alpha variant first and the Delta variant later,
386 have been the most rapidly expanding VOCs in Europe and the USA in 2021
387 ([https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html)
388 [people.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html)). Interestingly, a recent study using an assay similar to the Jurkat-S FC
389 assay but based on the human B cell line Ramos, has also shown that booster
390 vaccination with BNT increases the titer of anti-S antibodies against the Wuhan strain
391 but not against the Alpha and Beta variants (11).

392 Although our study is limited to measuring the presence of IgG1 against the S
393 protein of SARS-CoV-2, we think our results are relevant to evaluate the overall
394 humoral response, given that IgG1 is the most abundant immunoglobulin in human
395 blood and has potent effector capacities by being able to both fix complement and bind
396 to Fc receptors [19]. Our results showing a loss of relative reactivity with the current
397 VOCs suggest that third doses of the present vaccines, based on the Wuhan

sequence, to the general population might not be the best approach to increase the immunity to the emerging VOCs. In our opinion, a third dose should be limited to the population that has been demonstrated to have been poorly responsive to the first two prime and boost doses and not to the general population.

402

403 **Funding**

This work was funded by intramural grant CSIC-COVID19-004: 202020E081 (to B.A.) and CSIC-COVID19-004: 202020E165 (to MF). L.H has been supported by an FPI fellowship from the Spanish Ministry of Science and Innovation. I.B. has been supported by an H2020-MSCA-ITN-2016 training network grant of the European Union (GA 721358).

409 **Acknowledgments**

We are indebted to Valentina Blanco and Tania Gómez for their expert technical assistance. We thank all volunteers of the CBM, school teachers, “Hospital 12 de Octubre” and “Hospital Universitario de la Princesa” for generously participating in the study.

414 **Author Contributions**

LH and PD performed research and analyzed the data; IB helped with experimentation; SR-P, MQ, RL-G, PA-V, MAL, E.-A., SA, and AO provided clinical samples and data and revised the manuscript; MF and HMvS analyzed data and supervised research, BA supervised and designed research, analyzed data and wrote the manuscript.

419 **Conflict of interest**

The authors have issued a patent application owned by CSIC.

421 **DATA AVAILABILITY**

422 This study includes no data deposited in external repositories. Jurkat-S cells are available
423 for academic research upon request to B. Alarcón.

424

425 REFERENCES

- 426 1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
427 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*.
428 2020;383(27):2603-15.
- 429 2. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety
430 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an
431 interim analysis of four randomised controlled trials in Brazil, South Africa, and the
432 UK. *The Lancet*. 2021;397(10269):99-111.
- 433 3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
434 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384(5):403-
435 16.
- 436 4. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al.
437 Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl*
438 *J Med*. 2021;384(23):2187-201.
- 439 5. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.
440 Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med*.
441 2021;384(22):2092-101.
- 442 6. Muir K-L, Kallam A, Koepsell SA, Gundabolu K. Thrombotic Thrombocytopenia after
443 Ad26.COV2.S Vaccination. *N Engl J Med*. 2021;384(20):1964-5.
- 444 7. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
445 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*.
446 2021;596(7871):276-80.
- 447 8. 1. Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O'Horo JC,
448 et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during
449 periods of Alpha and Delta variant prevalence. :34.2021; .08.06.21261707.
- 450 9. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of
451 SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections,

- 452 Associated with Large Public Gatherings — Barnstable County, Massachusetts,
453 July 2021. MMWR Morb Mortal Wkly Rep.2021;70(31):1059-62.
- 454 10. Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang
455 JM, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in
456 Solid Organ Transplant Recipients: A Case Series. Ann Intern
457 Med.2021;174(9):1330-2.
- 458 11. Venter M, Richter K. Towards effective diagnostic assays for COVID-19: a
459 review. J Clin Pathol.2020;73(7):370-7.
- 460 12. Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci
461 Transl Med. 2020;12(546):eabc1931.
- 462 13. Horndler L, Delgado P, Abia D, Balabanov I, Martínez-Fleta P, Cornish G, et al.
463 Flow cytometry multiplexed method for the detection of neutralizing human
464 antibodies to the native SARS-CoV-2 spike protein. EMBO Mol Med. 2021;13(3)
- 465 14. Burton DR, Hangartner L. Broadly Neutralizing Antibodies to HIV and Their Role
466 in Vaccine Design. Annu Rev Immunol.2016;34(1):635-59.
- 467 15. van Schooten J, van Gils MJ. HIV-1 immunogens and strategies to drive
468 antibody responses towards neutralization breadth. Retrovirology. diciembre de
469 2018;15(1):74.
- 470 16. Kubo M, Miyauchi K. Breadth of Antibody Responses during Influenza Virus
471 Infection and Vaccination. Trends in Immunology. 2020;41(5):394-405.
- 472 17. Tea F, Ospina Stella A, Aggarwal A, Ross Darley D, Pilli D, Vitale D, et al.
473 SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging
474 viral variants. PLoS Med.2021;18(7):e1003656.
- 475 18. Vesper N, Ortiz Y, Bartels-Burgahn F, Yang J, de la Rosa K, Tenbusch M, et al.
476 A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against
477 SARS-CoV-2 Spike and Its Variants. Front Immunol.2021;12:730766.
- 478 19. Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular
479 properties of human IgG subclasses and their implications for designing therapeutic

480 monoclonal antibodies against infectious diseases. Molecular Immunology.
 481 2015;67(2):171-82.
 482 20. Martínez-Martín N, Risueño RM, Morreale A, Zaldívar I, Fernández-Arenas E,
 483 Herranz F, et al. Cooperativity Between T Cell Receptor Complexes Revealed by
 484 Conformational Mutants of CD3 ζ .2009.2(83).
 485

486 **Figures**

487 **Fig 1. Generation of anti-S protein antibodies in response to the first and second** 488 **priming-booster doses of different vaccines.**

489 **(A)** Generation of antibodies against the S protein of the Wuhan strain 3 weeks (BNT)
490 or 4 weeks (Moderna, ChAd and Ad26) after the first, priming, dose of vaccine to
491 previously uninfected individuals. The ratio of the mean fluorescence intensities (MFI)
492 of anti-S staining and anti-EGFR staining was calculated for each serum sample and
493 normalized to the value of the positive control (C+) sample. All sera were used at a
494 1:50 dilution. Box and whiskers plots to represent minimum and maximum values as
495 well as the median, and the mean (the mean with a cross) is shown. * $p < 0.05$; **
496 $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$; ns, not significant (one-way ANOVA test).

497 **(B)** Generation of antibodies against the S protein of the Wuhan variant strain 3 weeks
498 (BNT) or 4 weeks (Moderna, ChAd and Ad26) after the first, priming, dose of vaccine
499 and 4 weeks (all vaccines) after the second, booster dose of vaccine. The ratio mean
500 fluorescence intensities (MFI) of anti-S staining and anti-EGFR staining was calculated
501 for each serum sample and normalized to the value of the positive control (C+) sample.
502 All sera were used at a 1:50 dilution. Box and whiskers plots to represent minimum and
503 maximum values as well as the median, and the mean (the mean with a cross) are
504 shown. The number of samples for each vaccine is shown in the graph. ** $p < 0.01$; ****
505 $p < 0.0001$; ns, not significant (one-way ANOVA test).

506 **Fig 2. Effect of vaccination on the relative recognition of the Alpha and Wuhan** 507 **variants by sera of vaccinated individuals.**

508 **(A)** Generation of antibodies against the S protein of the Alpha variant 3 weeks (BNT)
509 or 4 weeks (Moderna, ChAd and Ad26) after the first, priming, dose of vaccine and 4
510 weeks (all vaccines) after the second, booster dose of vaccine. The ratio mean
511 fluorescence intensities (MFI) of anti-S staining and GFP staining was calculated for

each serum sample and normalized to the value of the positive control (C+) sample. All sera were used at a 1:50 dilution. Box and whiskers plots to represent minimum and maximum values as well as the median, and the mean (the mean with a cross) are shown. The number of samples for each vaccine is shown in the graph. ** $p < 0.01$; **** $p < 0.0001$; ns, not significant (one-way ANOVA test).

(B) Gating strategy to measure binding to the Wuhan and Alpha variants. Jurkat-S(Wuhan) and Jurkat-S(Alpha) cells were mixed in 1:1 ratio and incubated with either a 1:50 dilution of a positive control serum (C+) from a patient of the first wave in 2020 or a negative control serum (C-) obtained before the COVID-19 pandemics. Cells were subsequently incubated with mouse anti-human IgG1-PE and mouse anti-human EGFR-BV421 antibodies. After incubation, cells were gated according to lymphocyte FSC-A and SSC-A and subsequently on 7-AAD negative cells (7-AAD+ are dead cells). Live cells were subsequently gated on the FL1 channel (for GFP+ cells) and on the FL7 channel (huEGFRt+ cells). Both GFP+ and huEGFRt+ cells were separately analyzed for the fluorescence intensity of anti-IgG1 (S protein, FL2) versus GFP (for Jurkat-S(Alpha)) or for the fluorescence intensity of anti-IgG1 (S protein, FL2) versus EGFR (for Jurkat-S(Wuhan)). A diagonal lane is plotted on the bicolor contour plots corresponding to the C+ staining to indicate a relationship between S protein expression and either GFP or huEGFRt.

(C) Relative reactivity of the sera tested in (A) against the Alpha and Wuhan variants measured according to the (S/GFP ratio) / (S/EGFR ratio) and plotted individually for each serum donor. **** $p < 0.0001$; ns, not significant (one-way ANOVA test).

Fig 3. Multiplexed method to measure the reactivity of IgG1 antibodies with the S protein of the Wuhan, Alpha, Delta and Kappa variants.

Gating strategy to measure binding to the Wuhan, Alpha, Delta and Kappa variants. Jurkat-S(Wuhan), Jurkat-S(Alpha), Jurkat-S(Delta) and Jurkat-S(Kappa) cells were

538 mixed in 1:1:1:1 ratio and incubated with either a 1:50 dilution of a positive control
539 serum (C+) from a patient of the first wave in 2020 or a negative control serum (C-)
540 obtained before the COVID-19 pandemics. Cells were subsequently incubated with
541 mouse anti-human IgG1-PE, mouse anti-CD3-APC and mouse anti-human EGFR-
542 BV421 antibodies. After incubation, cells were gated according to lymphocyte FSC-A
543 and SSC-A and subsequently on 7-AAD negative cells (7-AAD+ are dead cells). Live
544 cells were subsequently gated on the FL1 channel (for CD3+ cells) and on the FL7
545 channel (huEGFRt+ cells). This allowed to distinguish four populations of cells:
546 EGFR+CD3+ (Jurkat-S[Wuhan], EGFR⁻CD3+ (Jurkat-S[Alpha]), EGFR+CD3⁻ (Jurkat-
547 S[Delta]) and EGFR⁻CD3⁻ (Jurkat-S[Kappa]). The cells were split between CD3+ and
548 CD3⁻ cells and subsequently analyzed according to EGFR and GFP expression (FL7
549 and FL1 channels). The four cell populations were separately analyzed for the
550 fluorescence intensity of anti-IgG1 (S protein, FL2) versus GFP (for Jurkat-S[Alpha]
551 and Jurkat-S[Kappa]) and for the fluorescence intensity of anti-IgG1 (S protein, FL2)
552 versus EGFR (for Jurkat-S[Wuhan] and Jurkat-S[Delta]). A diagonal lane is plotted on
553 the bicolor contour plots corresponding to the C+ staining to indicate a relationship
554 between S protein expression and either GFP or huEGFRt.

555 **Fig 4. Follow-up of the antibody response to vaccination in nursing homes.**

556 **(A)** Generation of antibodies against the S protein of the Wuhan, Alpha, Delta and
557 Kappa variants before (pre-Vacc) and after vaccination with the first dose (PD1) and
558 the second dose (PD2) of BNT/Pfizer. The normalized S/EGFR ratio for reactivity with
559 the Wuhan and Delta variants, and the S/GFP ratio for reactivity with the Alpha and
560 Kappa variants was measured as a quantitative calculation of IgG1 anti-S antibody
561 content. Sera were all used at a 1:50 dilution. Box and whiskers plots to represent
562 minimum and maximum values as well as the median, and the mean (the mean with a
563 cross) are shown. * $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$ (one-way ANOVA test).

564 **(B)** Relative reactivity of the sera tested in (A) against the Alpha, Delta and Kappa
565 variants versus the Wuhan strain was calculated according to the ratio of S/EGFR or
566 S/GFP ratios and plotted individually for each serum donor. **** $p < 0.0001$ (one-way
567 ANOVA test).

568

569 **Supplementary Material**

570 **Fig S1. Conversion between normalized ratio and WHO standards 21/234**
571 **(Wuhan-1).**

572 The international WHO working standard 21/234 was used to obtain a calibration
573 between the normalized S/EGFR MFI ratio on Jurkat-S(Wuhan) cells and Binding
574 Antibody Units (BAU). The datapoints were adjusted to a sigmoidal 4PL fit, where X is
575 in log10 (concentration) with a $R^2 = 0.9980$.

576 **Fig S2. Alignment of the amino acid sequences of the S protein of the Wuhan,**
577 **Alpha, Delta and Kappa variants of SARS-CoV-2.**

578 Amino acid mutations found in the Alpha, Delta or Kappa variants are shown in red
579 bold type. Alpha has 5 amino acid replacements and two amino acid deletions
580 compared to the reference Wuhan strain; Delta has 3 amino acid replacements and
581 Kappa has 4. The sequence corresponding to the Receptor Binding Domain (RBD) is
582 boxed. Alpha has just one amino acid (N to Y) replacement in the RBD, Kappa two (L
583 to R and E to Q) and Delta one (L to R).

584 **Fig S3. Titration of the different Jurkat-S variant cell lines**

585 Serial dilutions of the positive control serum (C+) used in Fig. 1 and Fig. 2 was tested
586 on the 4 Jurkat-S cell lines to determine their response to decreasing concentrations of
587 antibody. A pre-COVID human serum (dilution 1:50) was used as negative control
588 (grey squares).

589 **Fig S4. Spike protein expression at the plasma membrane**

590 Mid-plane optical sections of Jurkat-S cells expressing the indicated variants and
 591 stained with a mouse monoclonal anti-S protein of SARS-CoV-2 (in green) and a
 592 CD45-PE antibody (in red) as a plasma membrane marker. The cell nuclei were
 593 stained with DAPI.

594

595 **Table S1. Experimental data of Wuhan and Alpha variants**

596 **Table S2. Experimental data combining Wuhan, Alpha, Delta and Kappa variants**

Figure 1

A

IgG1 anti-S (Alpha)

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.12.21261952>; this version posted March 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

B

C

Alpha/Wuhan ratio

Figure 2

Figure 3

INDIVIDUALS AT NURSERY HOMES RECOVERED OF COVID-19 INFECTION AND VACCINATED WITH BNT

A

B

Figure 4

Conversion between normalized MFI ratios and WHO standards 21/234 (Wuhan-1)

Figure S1

Alpha	1	M L L L V T S L L L C E L P H P A F L L I P Q C V N L T T R T Q L P P A Y T N S F T R G V Y Y P D K V F R S S V L H S T Q D L F L P F F S N V T W F H A I H V S G T N G T K R F D N
Kappa	1	M L L L V T S L L L C E L P H P A F L L I P Q C V N L T T R T Q L P P A Y T N S F T R G V Y Y P D K V F R S S V L H S T Q D L F L P F F S N V T W F H A I H V S G T N G T K R F D N
Delta	1	M L L L V T S L L L C E L P H P A F L L I P Q C V N L T T R T Q L P P A Y T N S F T R G V Y Y P D K V F R S S V L H S T Q D L F L P F F S N V T W F H A I H V S G T N G T K R F D N
Wuhan	91	P V L P F N D G V Y F A S T E K S N I I R G W I F G T T L D S K T Q S L L I V N N A T N V V I K V C E F Q C N D P F L G V Y Y H K N N K S W M E S E F R V Y S S A N N C T F E Y V
Alpha	89	P V L P F N D G V Y F A S T E K S N I I R G W I F G T T L D S K T Q S L L I V N N A T N V V I K V C E F Q C N D P F L G V - Y H K N N K S W M E S E F R V Y S S A N N C T F E Y V
Kappa	91	P V L P F N D G V Y F A S T E K S N I I R G W I F G T T L D S K T Q S L L I V N N A T N V V I K V C E F Q C N D P F L G V Y Y H K N N K S W M K S E F R V Y S S A N N C T F E Y V
Delta	91	P V L P F N D G V Y F A S T E K S N I I R G W I F G T T L D S K T Q S L L I V N N A T N V V I K V C E F Q C N D P F L G V Y Y H K N N K S W M K S E F R V Y S S A N N C T F E Y V
Wuhan	181	S Q P F L M D L E G K Q G N F K N L R E F V F K N I D G Y F K I Y S K H T P I N L V R D L P Q G F S A L E P L V D L P I G I N I T R F Q T L L A L H R S Y L T P G D S S S G W T A G
Alpha	178	S Q P F L M D L E G K Q G N F K N L R E F V F K N I D G Y F K I Y S K H T P I N L V R D L P Q G F S A L E P L V D L P I G I N I T R F Q T L L A L H R S Y L T P G D S S S G W T A G
Kappa	181	S Q P F L M D L E G K Q G N F K N L R E F V F K N I D G Y F K I Y S K H T P I N L V R D L P Q G F S A L E P L V D L P I G I N I T R F Q T L L A L H R S Y L T P G D S S S G W T A G
Delta	181	S Q P F L M D L E G K Q G N F K N L R E F V F K N I D G Y F K I Y S K H T P I N L V R D L P Q G F S A L E P L V D L P I G I N I T R F Q T L L A L H R S Y L T P G D S S S G W T A G
Wuhan	271	A A A Y Y V G Y L Q P R T F L L K Y N E N G T I T D A V D C A L D P L S E T K C T L K S F T V E K G I Y Q T S N F R V Q P T E S I V R F P N I T N L C P F G E V F N A T R F A S V Y
Alpha	268	A A A Y Y V G Y L Q P R T F L L K Y N E N G T I T D A V D C A L D P L S E T K C T L K S F T V E K G I Y Q T S N F R V Q P T E S I V R F P N I T N L C P F G E V F N A T R F A S V Y
Kappa	271	A A A Y Y V G Y L Q P R T F L L K Y N E N G T I T D A V D C A L D P L S E T K C T L K S F T V E K G I Y Q T S N F R V Q P T E S I V R F P N I T N L C P F G E V F N A T R F A S V Y
Delta	271	A A A Y Y V G Y L Q P R T F L L K Y N E N G T I T D A V D C A L D P L S E T K C T L K S F T V E K G I Y Q T S N F R V Q P T E S I V R F P N I T N L C P F G E V F N A T R F A S V Y
Wuhan	361	A W N R K R I S N C V A D Y S V L Y N S A S F S T F K C Y G V S P T K L N D L C F T N V Y A D S F V I R G D E V R Q I A P G Q T G K I A D Y N Y K L P D D F T G C V I A W N S N N L
Alpha	358	A W N R K R I S N C V A D Y S V L Y N S A S F S T F K C Y G V S P T K L N D L C F T N V Y A D S F V I R G D E V R Q I A P G Q T G K I A D Y N Y K L P D D F T G C V I A W N S N N L
Kappa	361	A W N R K R I S N C V A D Y S V L Y N S A S F S T F K C Y G V S P T K L N D L C F T N V Y A D S F V I R G D E V R Q I A P G Q T G K I A D Y N Y K L P D D F T G C V I A W N S N N L
Delta	361	A W N R K R I S N C V A D Y S V L Y N S A S F S T F K C Y G V S P T K L N D L C F T N V Y A D S F V I R G D E V R Q I A P G Q T G K I A D Y N Y K L P D D F T G C V I A W N S N N L
Wuhan	451	D S K V G G N Y N Y L Y R L F R K S N L K P F E R D I S T E I Y Q A G S T P C N G V E G F N C Y F P L Q S Y G F Q P T N G V G Y Q P Y R V V L S F E L L H A P A T V C G F K K S T
Alpha	448	D S K V G G N Y N Y L Y R L F R K S N L K P F E R D I S T E I Y Q A G S T P C N G V E G F N C Y F P L Q S Y G F Q P T Y G V G Y Q P Y R V V L S F E L L H A P A T V C G F K K S T
Kappa	451	D S K V G G N Y N Y R Y R L F R K S N L K P F E R D I S T E I Y Q A G S T P C N G V Q G F N C Y F P L Q S Y G F Q P T N G V G Y Q P Y R V V L S F E L L H A P A T V C G F K K S T
Delta	451	D S K V G G N Y N Y R Y R L F R K S N L K P F E R D I S T E I Y Q A G S T P C N G V E G F N C Y F P L Q S Y G F Q P T N G V G Y Q P Y R V V L S F E L L H A P A T V C G F K K S T
Wuhan	541	N L V K N K C V N F N F N G L T G T G V L T E S N K K F L P F Q Q F G R D I A D T T D A V R D P Q T L E I L D I T P C S F G G V S V I T P G T N S N Q V A V L Y Q D V N C T E V P
Alpha	538	N L V K N K C V N F N F N G L T G T G V L T E S N K K F L P F Q Q F G R D I D T T D A V R D P Q T L E I L D I T P C S F G G V S V I T P G T N S N Q V A V L Y Q D V N C T E V P
Kappa	541	N L V K N K C V N F N F N G L T G T G V L T E S N K K F L P F Q Q F G R D I A D T T D A V R D P Q T L E I L D I T P C S F G G V S V I T P G T N S N Q V A V L Y Q D V N C T E V P
Delta	541	N L V K N K C V N F N F N G L T G T G V L T E S N K K F L P F Q Q F G R D I A D T T D A V R D P Q T L E I L D I T P C S F G G V S V I T P G T N S N Q V A V L Y Q D V N C T E V P
Wuhan	631	V A I H A D Q L T P T W R V Y S T G S N V F Q T R A G C L I G A E H V N N S Y E C D I P I G A G I C A S Y Q T Q T N S P R R A R S V A S Q S I I A Y T M S L G A E N S V A Y S N N S
Alpha	628	V A I H A D Q L T P T W R V Y S T G S N V F Q T R A G C L I G A E H V N N S Y E C D I P I G A G I C A S Y Q T Q T N S H R R A R S V A S Q S I I A Y T M S L G A E N S V A Y S N N S
Kappa	631	V A I H A D Q L T P T W R V Y S T G S N V F Q T R A G C L I G A E H V N N S Y E C D I P I G A G I C A S Y Q T Q T N S H R R A R S V A S Q S I I A Y T M S L G A E N S V A Y S N N S
Delta	631	V A I H A D Q L T P T W R V Y S T G S N V F Q T R A G C L I G A E H V N N S Y E C D I P I G A G I C A S Y Q T Q T N S H R R A R S V A S Q S I I A Y T M S L G A E N S V A Y S N N S
Wuhan	721	I A I P T N F T I S V T T E I L P V S M T K T S V D C T M Y I C G D S T E C S N L L Q Y G S F C T Q L N R A L T G I A V E Q D K N T Q E V F A Q V K Q I Y K T P P I K D F G G F N
Alpha	718	I A I P T N F T I S V T T E I L P V S M T K T S V D C T M Y I C G D S T E C S N L L Q Y G S F C T Q L N R A L T G I A V E Q D K N T Q E V F A Q V K Q I Y K T P P I K D F G G F N
Kappa	721	I A I P T N F T I S V T T E I L P V S M T K T S V D C T M Y I C G D S T E C S N L L Q Y G S F C T Q L N R A L T G I A V E Q D K N T Q E V F A Q V K Q I Y K T P P I K D F G G F N
Delta	721	I A I P T N F T I S V T T E I L P V S M T K T S V D C T M Y I C G D S T E C S N L L Q Y G S F C T Q L N R A L T G I A V E Q D K N T Q E V F A Q V K Q I Y K T P P I K D F G G F N
Wuhan	811	F S Q I L P D P S K P S K R S F I E D L L F N K V T L A D A G F I K Q Y G D C L G D I A A R D L I C A Q K F N G L T V L P L L T D E M I A Q Y T S A L L A G T I T S G W T F G A G
Alpha	808	F S Q I L P D P S K P S K R S F I E D L L F N K V T L A D A G F I K Q Y G D C L G D I A A R D L I C A Q K F N G L T V L P L L T D E M I A Q Y T S A L L A G T I T S G W T F G A G
Kappa	811	F S Q I L P D P S K P S K R S F I E D L L F N K V T L A D A G F I K Q Y G D C L G D I A A R D L I C A Q K F N G L T V L P L L T D E M I A Q Y T S A L L A G T I T S G W T F G A G
Delta	811	F S Q I L P D P S K P S K R S F I E D L L F N K V T L A D A G F I K Q Y G D C L G D I A A R D L I C A Q K F N G L T V L P L L T D E M I A Q Y T S A L L A G T I T S G W T F G A G
Wuhan	901	A A L Q I P F A M Q M A Y R F N G I G V T Q N V L Y E N Q K L I A N Q F N S A I G K I Q D S L S S T A S A L G K L Q D V V N Q N A Q A L N T L V K L S S N F G A I S S V L N D I L
Alpha	898	A A L Q I P F A M Q M A Y R F N G I G V T Q N V L Y E N Q K L I A N Q F N S A I G K I Q D S L S S T A S A L G K L Q D V V N Q N A Q A L N T L V K L S S N F G A I S S V L N D I L
Kappa	901	A A L Q I P F A M Q M A Y R F N G I G V T Q N V L Y E N Q K L I A N Q F N S A I G K I Q D S L S S T A S A L G K L Q D V V N Q N A Q A L N T L V K L S S N F G A I S S V L N D I L
Delta	901	A A L Q I P F A M Q M A Y R F N G I G V T Q N V L Y E N Q K L I A N Q F N S A I G K I Q D S L S S T A S A L G K L Q D V V N Q N A Q A L N T L V K L S S N F G A I S S V L N D I L
Wuhan	991	S R L D K V E A E V Q I D R L I T G R L Q S L Q T Y V T Q Q L I R A A E I R A S A N L A A T K M S E C V L G Q S K R V D F C G K G Y H L M S F P Q S A P H G V V F L H V T Y V P A Q
Alpha	988	A R L D K V E A E V Q I D R L I T G R L Q S L Q T Y V T Q Q L I R A A E I R A S A N L A A T K M S E C V L G Q S K R V D F C G K G Y H L M S F P Q S A P H G V V F L H V T Y V P A Q
Kappa	991	S R L D K V E A E V Q I D R L I T G R L Q S L Q T Y V T Q Q L I R A A E I R A S A N L A A T K M S E C V L G Q S K R V D F C G K G Y H L M S F P Q S A P H G V V F L H V T Y V P A Q
Delta	991	S R L D K V E A E V Q I D R L I T G R L Q S L Q T Y V T Q Q L I R A A E I R A S A N L A A T K M S E C V L G Q S K R V D F C G K G Y H L M S F P Q S A P H G V V F L H V T Y V P A Q
Wuhan	1081	E K N F T T A P A I C H D G K A H F P R E G V F V S N G T H W F V T Q R N F Y E P Q I I T D N T F V S G N C D V V I G I V N N T V Y D P L Q P E L D S F K E E L D K Y F K N H T S
Alpha	1078	E K N F T T A P A I C H D G K A H F P R E G V F V S N G T H W F V T Q R N F Y E P Q I I T H N T F V S G N C D V V I G I V N N T V Y D P L Q P E L D S F K E E L D K Y F K N H T S
Kappa	1081	E K N F T T A P A I C H D G K A H F P R E G V F V S N G T H W F V T Q R N F Y E P Q I I T D N T F V S G N C D V V I G I V N N T V Y D P L Q P E L D S F K E E L D K Y F K N H T S
Delta	1081	E K N F T T A P A I C H D G K A H F P R E G V F V S N G T H W F V T Q R N F Y E P Q I I T D N T F V S G N C D V V I G I V N N T V Y D P L Q P E L D S F K E E L D K Y F K N H T S
Wuhan	1171	P D V D L G D I S G I N A S V V N I Q K E I D R L N E V A K N L N E S L I D L Q E L G K Y E Q Y I K W P W Y I W L G F I A G L I A I V M V T I M L C C M T S C C S C L K G C C S C G
Alpha	1168	P D V D L G D I S G I N A S V V N I Q K E I D R L N E V A K N L N E S L I D L Q E L G K Y E Q Y I K W P W Y I W L G F I A G L I A I V M V T I M L C C M T S C C S C L K G C C S C G
Kappa	1171	P D V D L G D I S G I N A S V V N I Q K E I D R L N E V A K N L N E S L I D L Q E L G K Y E Q Y I K W P W Y I W L G F I A G L I A I V M V T I M L C C M T S C C S C L K G C C S C G
Delta	1171	P D V D L G D I S G I N A S V V N I Q K E I D R L N E V A K N L N E S L I D L Q E L G K Y E Q Y I K W P W Y I W L G F I A G L I A I V M V T I M L C C M T S C C S C L K G C C S C G
Wuhan	1261	S C C K F E D D S E P V L K G V K L H Y T
Alpha	1258	S C C K F E D D S E P V L K G V K L H Y T
Kappa	1261	S C C K F E D D S E P V L K G V K L H Y T
Delta	1261	S C C K F E D D S E P V L K G V K L H Y T

RBD

Figure S2

Figure S3

Figure S4